McKesson to buy Precision Medicine Group for $2.25B in oncology push
What's the deal? McKessonDealroom has a profile for this one. Try Dealroom → (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group for roughly $2.25 billion. The deal expands the healthcare services company's clinical research and biopharma commercialization capabilities within its Oncology & Multispecialty business.
What each side brings: Precision Medicine Group works with life sciences companies to move therapies from early development through clinical research, market access, and commercialization. The acquisition adds its global clinical research organization, biomarker intelligence, laboratory services, and market access consulting to McKesson's platform.
What changes? After close, Precision Medicine Group will operate within McKesson's Oncology & Multispecialty segment, sitting alongside businesses that serve specialty care providers and life sciences companies. The deal remains subject to customary closing conditions, including regulatory clearances.
Why it matters: The move reinforces oncology as a strategic growth area for McKesson. Rather than building the capabilities internally, McKesson gains an established global operation spanning drug development and commercialization.
What they're saying: "This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy," McKesson chair and chief executive officer Brian Tyler said. Precision Medicine Group CEO Margaret Keegan said the two firms will "bring a broader set of capabilities to biopharma companies, supporting them through the development and commercialization process."
The signal: The $2.25 billion price marks the scale of McKesson's push beyond pharmaceutical distribution into higher-value clinical services. As drug developers increasingly need integrated trial, laboratory, biomarker, and market access expertise, McKesson is buying a way to participate more deeply in how new medicines reach patients.
Read more: citybiz.co
Image credit: Generated with Gemini
